Cantor Fitzgerald initiated coverage of Context Therapeutics (CNTX) with an Overweight rating. Context is an under-the-radar oncology company developing three T-cell engagers, and as the company has been in execution mode, it is now approaching multiple data inflection points in 2026, the analyst tells investors in a research note. Lead program, CTIM-76, could prove to be a viable drug in ovarian cancer, the firm argues.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CNTX: